Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 7/2013

01-07-2013 | PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Current Perspectives on Ophthalmic Manifestations of Childhood Rheumatic Diseases

Authors: Neal V. Palejwala, Steven Yeh, Sheila T. Angeles-Han

Published in: Current Rheumatology Reports | Issue 7/2013

Login to get access

Abstract

Inflammatory eye diseases are an important manifestation of many pediatric rheumatologic conditions. Early screening and diagnosis are imperative as these illnesses can not only result in significant visual morbidity but are also an indicator of systemic inflammation. Time to presentation of ocular inflammation varies significantly and can range from many years prior to the onset of systemic symptoms to well after the diagnosis of the rheumatologic disorder. Due to this variability in presentation, careful monitoring by an ophthalmologist is vital to preventing ocular complications and preserving vision. Both local and systemic immunosuppressive medications have been effective in the management of ocular disease. In this review, we will focus on the known ophthalmologic manifestations of common pediatric rheumatologic diseases and discuss recent advances in therapeutic considerations for these conditions.
Literature
1.
Reiff A. Ocular complications of childhood rheumatic diseases: Nonuveitic inflammatory eye diseases. Current Rheumatology Reports. 2009;11:226–32.PubMedCrossRef
2.
3.
Zierhut M, Michels H, Stubiger N, et al. Uveitis in children. Int Ophthalmol Clin. 2005;45:135–56.PubMedCrossRef
4.
5.
Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed
6.
Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2003;14:395–8.PubMedCrossRef
7.
Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-term follow-up study. Arthritis & Rheumatism. 2007;56(2):647–57.CrossRef
8.
Oren B, Sehgal A, Simon JW, et al. The prevalence of uveitis in juvenile rheumatoid arthritis. J AAPOS. 2001;5:2–4.PubMedCrossRef
9.
Aggarwal A, Misra R. Juvenile chronic arthritis in India: is it different from that seen in Western countries? Rhumatol Int. 1994;14:53–6.CrossRef
10.
• Qian Y, Acharya NR. Juvenile idiopathic arthritis-associated uveitis. Current Opinion in Ophthalmology. 2010;21:468–72. This article nicely summarizes the recent literature about JIA-uveitis.PubMedCrossRef
11.
Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104:236–44.PubMedCrossRef
12.
de Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003;87:879–84.PubMedCrossRef
13.
Thorne JE, Woreta F, Kedhar SR, et al. Juvenile idiopathic arthritis-associated uveitis: Incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143(5):840–46.PubMedCrossRef
14.
Hoeve M, Ayuso VK, Schalij-Delfos NE, et al. The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty. Br J Ophthalmol. 2012;96:852–56.PubMedCrossRef
15.
Sabri K, Saurenmann RK, Silverman ED. Course, complications, and outcome of juvenile arthritis-related uveitis. Journal of AAPOS. 2008;12(6):539–45.PubMedCrossRef
16.
Marvillet I, Terrada C, Quartier P, et al. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine. 2009;76:383–88.PubMedCrossRef
17.
Gregory AC, Kempen JH, Daniel EB. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: The systemic immunosuppressive therapy for eye diseases study. Ophthalmology. 2013;120:186–92.PubMedCrossRef
18.
Woreta F, Thorne JE, Jabs DA, et al. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:647–55.PubMedCrossRef
19.
Section on Rheumatology and Section on Ophthalmology. Guidelines for ophthalmologic examination in children with juvenile rheumatoid arthritis. Pediatrics. 1993;92(2):295–6.
20.
Angeles-Han ST, Griffin KW, Harrison MJ, et al. Development of a vision-related quality of life instrument for children age 8–18 years for use in juvenile idiopathic arthritis-associated uveitis. Arthritis and Rheumatism. 2011;63(9):1254–61.CrossRef
21.
Paroli MP, Spinucci G, Fabiani C, Pivetti-Pezzi P. Retinal complications of juvenile idiopathic arthritis-related uveitis: a microperimetry and optical coherence tomography study. Ocul Immunol Inflamm. 2010;18(1):54–9.PubMedCrossRef
22.
Edelsten C, Lee V, Bentley CR, et al. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002;86:51–6.PubMedCrossRef
23.
Ayuso VK, ten Cate HAT, van der Does P, et al. Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2010;149:994–9.CrossRef
24.
Cabral DA, Petty RE, Malleson PN, et al.: Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol 21:2370–2375
25.
Hofer M, Southwood TR. Classification of childhood arthritis. Best Prac Res Clin Rheumatol. 2002;16:379–96.
26.
Horneff G, Burgos-Vargas R. Juvenile idiopathic arthritis. Sub-group characteristics and comparisons between rheumatoid arthritis–like subgroups and ankylosing spondylitis–like subgroups. Clin Exp Rheumatol. 2009;27:S131–8.PubMed
27.
• Scofield RH, Sestak AL. Juvenile spondyloarthropathies. Curr Rheumatol Rep. 2012;14:395–401. This article summarizes the current literature on juvenile spondyloarthropathies.PubMedCrossRef
28.
Stoll ML, Bhore R, Dempsy-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: Risk factors for sacroiliitis. J Rheumatol. 2010;37(11):2402–8.PubMedCrossRef
29.
Ozgocmen S, Ardicoglu O, Kamanli A. Pattern of Disease Onset, Diagnostic Delay, and Clinical Features in Juvenile Onset and Adult Onset Ankylosing Spondylitis. J Rheumatol. 2009;36:2830–3.PubMedCrossRef
30.
Liao CH, Huang JL. Juvenile ankylosing spondilitis with uveitis. Asian Pacific Journal of Allergy and Immunology. 2003;21:69–71.PubMed
31.
Silva-Ramírez B, Vargas-Alarcón G, Granados J, Burgos-Vargas R. HLA antigens and juvenile onset spondyloarthritides: negative association with non-B27 alleles. Clin Exp Rheumatol. 2005;23(5):721–3.PubMed
32.
33.
Kollnberger S, Bird LA, Roddis M, et al. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol. 2004;173:1699–710.PubMed
34.
Mear JP, Schreiber KL, Münz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol. 1999;163:6665–70.PubMed
35.
Cokington CD, Han DP. Bilateral nongranulomatous uveitis and a post-streptococcal syndrome. Am J Ophthalmol. 1991;112(5):595–6.
36.
Rehman S, Anand S, Reddy A, et al. Post streptococcal syndrome uveitis: a descriptive case series and literature review. Ophthalmology. 2006;113(4):701–6.CrossRef
37.
Nataneli N, Aguilera ZP, Rosenbaum PS, et al. Poststreptococcal keratouveitis associated with group C streptococcus pharyngitis. Clinical Ophthalmology. 2011;5:1257–59.PubMed
38.
Ansell B. Reactive arthritis/Reiter’s syndrome in children. Clin Exp Rheumatol. 1994;12:581–82.PubMed
39.
Keat A. Reiter’s syndrome and reactive arthritis in perspective. N Engl J Med. 1988;309:1606–15.CrossRef
40.
Manimegalai N, Rajamurugan A, Rajendran P, et al. Childhood reactive arthritis. J Clin Rheumatol. 2008;14(5):292–93.PubMedCrossRef
41.
Singsen B, Bernstein B, Koster-King K, Glovsky M, Hansen V. Reiter's syndrome in childhood. Arthritis Rheum. 1977;20(Suppl):402–7.PubMed
42.
Tinley C, Van Zyl L, Grötte R. Poststreptococcal syndrome uveitis in South African children. Br J Ophthalmol. 2012;96(1):87–9.PubMedCrossRef
43.
Kiss S, Letko E, Qamruddin S, Baltatzis S, Foster S. Ocular Manifestions of Reiter’s Syndrome. Ophthalmology. 2003;110:1764–69.PubMedCrossRef
44.
Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009 Aug;116(8):1544–51.
45.
Nikkhah H, Ramezani A, Ahmadieh H, et al. Childhood pars planitis; clinical features and outcomes. J Ophthalmic Vis Res. 2011;6(4):249–54.PubMed
46.
Donaldson MJ, Pulido JS, Herman DC, Diehl N, Hodge D. Pars planitis: A 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol. 2007;144:812–7.PubMedCrossRef
47.
Raja SC, Jabs DA, Dunn JP, et al. Pars planitis: clinical features and class II HLA association. Ophthalmology. 1999;106:594–9.PubMedCrossRef
48.
Arellans-Garcia L, Navarro-Lopez LP, Recillas- Gispert C. Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome. Ocul Immunol Inflamm. 2003;11:53–60.CrossRef
49.
Romero R, Peralta J, Sendagorta E, Abelairas J. Pars planitis in children: epidemiologic, clinical and therapeutic characteristics. J Pediatr Ophthalmol Strabismus. 2007;44:288–93.PubMed
50.
Guest S, Funkhouser E, Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clinical and Experimental Ophthalmology. 2001;29:81–4.PubMedCrossRef
51.
Cimaz R, Ansell BM. Sarcoidosis in the pediatric age. Clin Exp Rheumatol. 2002;20:231–7.PubMed
52.
Choi DE, Birnbaum AD, Oh F, Tessler HH, Goldstein DA. Pediatric uveitis secondary to probable, presumed, and biopsy-proven sarcoidosis. J Pediatr Ophthalmol Strabismus. 2011;48(3):157–62.PubMedCrossRef
53.
Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004;93:30–6.PubMedCrossRef
54.
Shetty AK, Gedalia A. Childhood sarcoidosis: a rare but fascinating disorder. Pediatr Rheumatol Online. 2008;6:6.CrossRef
55.
Shetty AK, Gedalia A. Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila). 1998;37:707–17.CrossRef
56.
Kataria S, Trevathan GE, Holland JE, Kataria YP. Ocular presentation of sarcoidosis in children. Clin Pediatr (Phila). 1983;22:793–7.CrossRef
57.
58.
James DG, Neville E, Langley DA. Ocular sarcoidosis. Trans Ophthalmol Soc UK. 1976;96:133–9.PubMed
59.
Khalatbari D, Stinnett S, McCallum RM, Jaffe GJ. Demographic-related variations in posterior segment ocular sarcoidosis. Ophthalmology. 2004;111:357–62.PubMedCrossRef
60.
Yanardag H, Pamuk ON. Lacrimal gland involvement in sarcoidosis: the clinical features of 9 patients. Swiss Med Wkly. 2003;133:388–91.PubMed
61.
Habibi S, Saleem MA, Ramanan AV. Juvenile systemic lupus erythematosus: review of clinical features and management. Indian Pediatrics. 2011;48:879–86.PubMedCrossRef
62.
Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999;42:1354–60.PubMedCrossRef
63.
Guiterrez-Suarez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the systemic lupus international collaborating clinics/American college of Rheumatology damage index based on the on analysis of 1,015 patients with juvenile-onset systemic lupus erthematosus. Arthritis & Rheumatism. 2006;54(9):2989–96.CrossRef
64.
Brunner HI, Gladman DD. Ibañez D, Urowitz MD, Silverman ED: Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58:556–62.PubMedCrossRef
65.
Font J, Cervera R, Espinosa G et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults.
66.
Almeida RT, Aikawa NE, Sallum AME, et al. Irreversible blindness in juvenile systemic lupus erythematosus. Lupus. 2011;20:95–7.PubMedCrossRef
67.
Avcin T, Silverman ED. Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16:627–33.PubMedCrossRef
68.
Montehermoso A, Cervera R, Font J, et al. Association of antiphopholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Sem Arth Rheum. 1999;28(5):326–32.CrossRef
69.
Hannouche D et al. Systemic lupus erythematosus with choroidopathy and serous retinal detachment. Int Ophthalmol. 1995;19:125–27.PubMedCrossRef
70.
Schwartz M, Roberts J. Membranous and vascular choroidopathy: two patterns of immune deposits in systemic lupus erythematosus. Clin Immunol Immunopathol. 1983;29:369–80.PubMedCrossRef
71.
Matsuo T et al. Multifocal pigment epithelial damages with serous retinal detachment in systemic lupus erythematosus. Ophthalmologica. 1987;195:97–102.PubMedCrossRef
72.
• Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: A review of the literature. Autoimmune Dis. 2012. This review summarizes the ocular complications that are commonly seen in systemic lupus erythematosus.
73.
Soylu M, Ozdemir G, Anli A. Pediatric uveitis in Southern Turkey. Ocul Immunol Inflamm. 1997;5:197–202.PubMedCrossRef
74.
Mochizuki M, Akduman L, Nussenblatt RB. Behcet’s disease. In: Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. St Louis: Mosby; 1996. p. 663–75.
75.
Fujikawa S, Suesmitus T. Behcet disease in children: A nationwide retrospective survery in Japan. Acta Paediatrica Japonica. 1997;39:285–89.PubMedCrossRef
76.
Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behcet disease: A descriptive study of 36 cases. Am J Ophthalmol. 2003;136(6):1114–19.PubMedCrossRef
77.
Koné-Paut I, Yurdakul S, Bahabri SA, et al. Clinical features of Behcet’s disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132:721–5.PubMedCrossRef
78.
Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S. Low prevalence of juvenile-onset Behçet’s disease with uveitis in East/South Asian people. Br J Ophthalmol. 2009;93(11):1428–30.PubMedCrossRef
79.
Atmaca L, Boyvat A, Yalcindag N, et al. Behcet disease in children. Ocular Immunology & Inflammation. 2011;19(2):103–7.CrossRef
80.
Colvard DM, Robertson DM, O’Duffy JD. The ocular manifestations of Behcet’s disease. Arch Ophthalmol. 1977;95:1813–15.PubMedCrossRef
81.
Citirik M, Berker N, Songur MS. Ocular findings in childhood-onset Behcet disease. J AAPOS. 2009;13:291–95.
82.
Pivetti-Pezzi P, Accorinti M, Abdulaziz MA, La Cava M, Torella M, Riso D. Behcet’s disease in children. Jpn J Ophthalmol. 1995;39:309–14.PubMed
83.
Kesen MR, Goldstein DA, Tessler HH. Uveitis associated with pediatric Behcet disease in the American Midwest. Am J Ophthalmol. 2008;146:819–27.PubMedCrossRef
84.
Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas H, Urgancioglu M. Uveitis in Behcet disease: An analysis of 880 patients. Am J Ophthalmol. 2004;138:373–80.PubMedCrossRef
85.
Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum. 2011;63:863–4.PubMedCrossRef
86.
Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum. 2009;60(11):3413–24.PubMedCrossRef
87.
Vanoni F, Bettinelli A, Keller F, et al. Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood. Pediatr Nephrol. 2010;25:205–12.PubMedCrossRef
88.
Schmidt J, Pulido JS, Matteson EL. Ocular manifestations of systemic disease: antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Ophthalmol. 2011;22:489–95.PubMedCrossRef
89.
Jiang B, Zhao YY, Wei SH. Granulomatosis with polyangiitis: The relationship between ocular and nasal disease. Ocul Immunol Inflamm. 2012 [Epub].
90.
Vischio JA, McCrary CT. Orbital Wegener's granulomatosis: a case report and review of the literature. Clin Rheumatol. 2008;27(10):1333–6.PubMedCrossRef
91.
Shiboski SC, Shiboski CH, Criswell LA et al. American college of rheumatology classification criteria for Sjogren’s syndrome: A data-driven expert consensus approach in the Sjogren’s international collaborative clinical alliance cohort. 2012; 64(4): 475–87
92.
Hernández-Molina G, Avila-Casado C, Cárdenas-Velázquez F, et al. Similarities and differences between primary and secondary Sjögren's syndrome. J Rheumatol. 2010;37(4):800–8.PubMedCrossRef
93.
Civilibal M, Canpolat N, Yurt A. A child with primary Sjogren Syndrome and a review of the literature. Clinical Pediatrics. 2007;46(8):738–42.PubMedCrossRef
94.
Cimaz R, Casadei A, Rose C, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162(10):661–65.PubMedCrossRef
95.
Houghton K, Malleson P, Cabral D, Petty R, Tucker L. Primary Sjogren’s syndrome in children and adolescents: are proposed diagnostic criteria applicable. J Rheumatol. 2005;32:2225–32.PubMed
96.
Bartunkova J, Sediva A, Vencovsky J, Tesar V. Primary Sjogren’s syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol. 1999;17:381–6.PubMed
97.
Stiller M, Golder W, Döring E, et al. Primary and secondary Sjögren's syndrome in children–a comparative study. Clin Oral Investig. 2000;4(3):176–82.PubMedCrossRef
98.
Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007–2008 nationwide survey. J Epidemiol. 2010;20(4):302–07.PubMedCrossRef
99.
Lin YT, Manlhiot C, Ching JC, et al. Repeated systemic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatr Int. 2010;52:699–706.PubMedCrossRef
100.
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation. 2004;110:2747–71.PubMedCrossRef
101.
Burke MJ, Rennebohm RM. Eye involvement in Kawasaki disease. J Pediatr Ophthalmol Strabismus. 1981;18:7–11.PubMed
102.
Kadyan A, Choi J, Headon MP. Disciform keratitis and optic disc swelling in Kawasaki disease: an unusual presentation. Eye. 2006;20(8):976–7.PubMedCrossRef
103.
Burns JC, Joffe L, Sargent RA, Glode MP. Anterior uveitis associated with Kawasaki syndrome. Pediatr Infect Dis. 1985;4:258–61.PubMedCrossRef
104.
Rennebohm RM, Burke MJ, Crowe W, et al. Anterior uveitis in Kawasaki’s disease. Am J Ophthalmol. 1981;91(4):535–37.PubMed
105.
Burke MJ, Rennebohm RM. Eye involvement in Kawasaki disease. J Pediatr Ophthalmol Strabismus. 1981;18(5):7–11.PubMed
106.
Farvardin M, Kashef S, Aleyasin S, et al. Sudden unilateral blindness in a girl with Kawasaki disease. J Pediatr Ophthalmol Strabismus. 2007;44:303–04.PubMed
107.
Grouteau E, Dubuisson C, Brochard K, et al. Severe global inflammatory involvement of ocular segments and optic disc swelling in a 12 year-old girl with Kawasaki disease. Eur J Ophthalmol. 2011;21:112–14.PubMedCrossRef
108.
Garweg JG, Suter C, Aebi-Ochsner. Macular oedema in Kawasaki syndrome. Gaefes Arch Clin Exp Ophthalmol. 2012;250:1101–04.CrossRef
109.
Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55:603–13.PubMedCrossRef
110.
• Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile-idiopathic arthritis uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436–41. This retrospective cohort study showed that >3 drops of topical corticosteroids was associated with a significantly increased risk of cataract formation.PubMedCrossRef
111.
Romero R, Peralta J, Sendagorta E, Abelairas J. Pars planitis in children: epidemiologic, clinical and therapeutic characteristics. J Pediatr Ophthalmol Strabismus. 2007;44(5):288–93.PubMed
112.
Beukelman T, Ringold S, Davis TE, et al. CARRA Registry Investigators. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39(9):1867–74.PubMedCrossRef
113.
Schatz CS, Uzel JL, Leininger L, et al. Immunosuppressants used in a steroid-sparing strategy for childhood uveitis. J Pediatr Ophthalmol Strabismus. 2007;44(1):28–34.PubMed
114.
Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252–7.PubMedCrossRef
115.
Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45(8):982–9.PubMedCrossRef
116.
Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34(5):1146–50.PubMed
117.
Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860–4.PubMedCrossRef
118.
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74–9. Infliximab and adalimumab appear to be effective and safe for the treatment of refractory uveitis.PubMedCrossRef
119.
Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(3):339–44.PubMedCrossRef
120.
Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44(6):1411–5.PubMedCrossRef
121.
Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44(8):1008–11.PubMedCrossRef
122.
Taban M, Dupps WJ, Mandell B, et al. Etanercept (enbrel)-associated in- flammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm. 2006;14:145–50.PubMedCrossRef
123.
Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol. 2008;35(9):1897–8.PubMed
124.
William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):231–3.PubMedCrossRef
125.
Sen HN, Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009;148(5):696–703.PubMedCrossRef
126.
Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: Indications, toxicities, and guidelines. J Am Acad Dermatol. 1993;28:764–70.PubMedCrossRef
127.
Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.PubMedCrossRef
128.
129.
• Angeles-Han ST, Griffin KW, Harrison MJ, et al. Development of a vision-related quality of life instrument for children ages 8–18 years for use in juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken). 2011;63(9):1254–61. This study provides evidence of the validity and reliability of the EYE-Q in the measurement of VRQOL.CrossRef
130.
Angeles-Han ST, Griffin KW, Lehman TJ, et al. The importance of visual function in the quality of life of children with uveitis. J AAPOS. Mar 15 2010.
Metadata
Title
Current Perspectives on Ophthalmic Manifestations of Childhood Rheumatic Diseases
Authors
Neal V. Palejwala
Steven Yeh
Sheila T. Angeles-Han
Publication date
01-07-2013
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 7/2013
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0341-3

Other articles of this Issue 7/2013

Current Rheumatology Reports 7/2013 Go to the issue

SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR)

Osteoimmunology and Bone Homeostasis: Relevance to Spondyloarthritis

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies

PEDIATRIC RHEUMATOLOGY (TJA LEHMAN, SECTION EDITOR)

Tocilizumab in Pediatric Rheumatology: The Clinical Experience

SYSTEMIC LUPUS ERYTHEMATOSUS (M PETRI, SECTION EDITOR)

Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Update on Oxalate Crystal Disease

COMPLEMENTARY AND ALTERNATIVE MEDICINE (SL KOLASINSKI, SECTION EDITOR)

Manipulative Therapy (Feldenkrais, Massage, Chiropractic Manipulation) for Neck Pain
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits